Corcept Therapeutics Incorporated (CORT) — ESG & Values Scores

Environment story

Corcept Therapeutics has not disclosed direct Scope 1 and Scope 2 emissions data, nor has it published a net-zero commitment or target year. The company operates as a biopharmaceutical firm with limited manufacturing footprint (reliance on third-party contract manufacturers and specialty pharmacies). No material resource-extraction or toxic-waste controversies identified in SEC filings. The company has disclosed tariff exposure related to imported pharmaceutical materials and API sourcing, which may increase operational carbon intensity indirectly through supply-chain disruptions. No verified investments in decarbonization infrastructure disclosed. Without emissions data or credible climate commitments, the E-pillar score reflects the absence of material environmental risks specific to Corcept's model, but lacks affirmative sustainability leadership.

Criticisms on file

Tariff exposure on imported pharmaceutical materials and API sourcing; company flagged tariff regime instability as operational cost risk.
Source: CORT 10-K, Risk Factors section, 'Actions by the federal government of the United States have created unprecedented legal, governmental, regulatory and economic uncertainty and risks that may adversely affect our business.'

Disclosed initiatives

Third-party manufacturer oversight

Corcept relies on contract manufacturers and vendors subject to FDA cGMP and regulatory inspections; no explicit ESG or sustainability audit framework disclosed.

Social story

Corcept Therapeutics has not disclosed CEO-to-median-worker pay ratio, workforce turnover rates, or diversity metrics (gender, race/ethnicity in leadership or workforce). No documented labor union activity, strikes, or NLRB complaints identified in 10-K. The company emphasizes patient support programs ('no patient with hypercortisolism will be denied access to our Products for financial reasons') and donations to independent charitable foundations for co-pay and premium assistance. However, lack of transparency on pay equity, leadership diversity, and labor practices limits scoring. Supply-chain ethics disclosures are minimal; the company does not manufacture active pharmaceutical ingredients and thus does not face direct exposure to conflict minerals (e.g., cobalt, lithium) typical of hardware/battery manufacturers. Management team reliance noted as a risk ('small management team'). Overall, the absence of material social controversies is offset by limited disclosure of progressive social policies.

Criticisms on file

Federal government investigation by U.S. Attorney's Office for the District of New Jersey (NJ USAO) initiated November 2021 regarding sale and promotion of Korlym, relationships with healthcare professionals, and reimbursement practices. Company cooperating; not currently considered a defendant.
Source: CORT 10-K, Risk Factors section, 'We may be subject to civil or criminal penalties if our marketing of our Products violates FDA regulations or health care fraud and abuse laws.'
Enhanced regulatory scrutiny of company-sponsored patient assistance programs and third-party charitable donations; risk of reduced or eliminated assistance due to heightened oversight.
Source: CORT 10-K, Risk Factors section, 'New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for our Products.'

Disclosed initiatives

Patient support and financial assistance programs

Company provides patient support programs and makes grants to independent charitable foundations to help financially needy patients with premium, co-pay, and co-insurance obligations for hypercortisolism treatment regardless of whether treatment includes Corcept products.

Ensures patient access to treatment irrespective of financial barriers.
Specialty pharmacy and pharmacy vendor oversight

Transitioned from Optime specialty pharmacy vendor to Curant in 2025-2026 for improved supply-chain reliability and patient support services.

Operational resilience; no explicit DEI or labor-relations standards disclosed for vendor selection.

Governance story

Corcept Therapeutics has not disclosed board independence percentage, share structure (single vs. dual-class), or annual lobbying expenditures in the 10-K. The company does not appear to operate under a dual-class voting structure (single class of common stock disclosed), which is a positive governance signal. No evidence of anti-competitive lobbying or climate-regulation weakening activities identified. However, the company faces material regulatory and compliance risks: (1) Federal investigation by NJ USAO into marketing and reimbursement practices (November 2021, ongoing); (2) FDA Refuse-to-File (CRL) for relacorilant NDA (December 2025); (3) Intellectual property litigation with Teva over Korlym generic (patent infringement claims dismissed by Federal Circuit, February 2026); (4) Off-label promotion risk under Anti-Kickback Statute and False Claims Act. The company's MD&A and risk disclosures reflect awareness of healthcare compliance obligations but limited affirmative governance transparency (e.g., no disclosed board committees, ESG governance structure, or third-party audit). Management succession risks noted ('small management team'). Overall, governance score reflects absence of major compliance breaches but limited proactive disclosure and ongoing regulatory headwinds.

Criticisms on file

U.S. Attorney's Office for the District of New Jersey (NJ USAO) investigation into Korlym sale, promotion, healthcare provider relationships, and reimbursement practices. Company received records subpoena in November 2021; investigation ongoing as of 10-K filing. Company states it is not currently considered a defendant but entity within scope of investigation.
Source: CORT 10-K, Risk Factors section, 'We may be subject to civil or criminal penalties if our marketing of our Products violates FDA regulations or health care fraud and abuse laws.'
FDA Complete Response Letter (CRL) issued December 30, 2025, declining approval of relacorilant NDA for hypercortisolism treatment. FDA stated additional efficacy evidence required despite GRACE trial meeting primary endpoint and GRADIENT providing confirmatory evidence.
Source: CORT 10-K, MD&A section, 'On December 30, 2025, the FDA issued a CRL declining to approve relacorilant for the proposed use.'
Patent infringement litigation with Teva Pharmaceutical Industries Limited over generic Korlym. Federal District Court ruled no infringement on December 29, 2023. Corcept appealed to U.S. Court of Appeals for the Federal Circuit, which affirmed non-infringement on February 19, 2026. Teva launched generic Korlym in January 2024.
Source: CORT 10-K, Risk Factors section, 'The availability of generic versions of Korlym could adversely affect our business, results of operations and financial position.'
Significant tariff exposure and trade policy uncertainty. Company flagged tariff regime instability, imposition of new tariffs, and abrupt reversals as material operational cost risks. Government actions cited as causing 'unprecedented legal, governmental, regulatory and economic uncertainty.'
Source: CORT 10-K, Risk Factors section, 'Actions by the federal government of the United States have created unprecedented legal, governmental, regulatory and economic uncertainty and risks that may adversely affect our business.'

Disclosed initiatives

Compliance policies and procedures

Company maintains policies and procedures prohibiting fraudulent and illegal activity by employees, contractors, and vendors; compliance with Anti-Kickback Statute, False Claims Act, HIPAA, and state healthcare fraud laws disclosed in risk factors.

Defensive posture; no affirmative ethics/compliance leadership program or third-party audit disclosed.
Regulatory engagement and transparency

Company cooperating with federal investigation by NJ USAO; submitted NDAs and MAAs for relacorilant to FDA and EMA; established structured clinical trial programs (GRACE, GRADIENT, ROSELLA, etc.) subject to regulatory oversight.

Engagement with regulators; regulatory rejections (CRL for relacorilant) and ongoing investigation reflect governance challenges.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Corcept Therapeutics Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Corcept Therapeutics Incorporated in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)